Finasteride

May be taken with or without food.

Women. Children. Pregnancy and lactation.

Patient with large residual urine and/or severely decreased urinary flow. Not indicated for the prevention of prostate cancer. Hepatic impairment. Patient Counselling Women of child-bearing potential or who are pregnant should not handle crushed or broken tab. Excreted in semen therefore use of condom is recommended. Monitoring Parameters Rule out other urological diseases (e.g. prostate cancer) before initiation of therapy. Perform digital rectal examination and other assessment for prostate cancer before and during therapy. Obtain new baseline prostate-specific antigen (PSA) level after ≥6 months of treatment then monitor periodically thereafter. Monitor for psychiatric symptoms, objective and subjective signs of relief of benign prostatic hyperplasia (e.g. improvement in urinary flow, reduction in symptoms of urgency, relief of difficulty in micturition).

Significant: Breast cancer, mood alterations (e.g. depressed mood, depression and rarely, suicidal ideation). Immune system disorders: Hypersensitivity reaction (e.g. angioedema, urticaria). Investigations: Decreased volume of ejaculate. Reproductive system and breast disorders: Impotence, decreased libido, ejaculation disorder, haematospermia, breast tenderness and enlargement, testicular pain, male infertility and/or poor seminal quality. Skin and subcutaneous tissue disorders: Rash, pruritus.

Drugs for Bladder & Prostate Disorders / Other Dermatologicals

D11AX10 - finasteride ; Belongs to the class of other dermatologicals.
G04CB01 - finasteride ; Belongs to the class of testosterone-5-alpha reductase inhibitors. Used in the treatment of benign prostatic hypertrophy.